Targeted Interferon Chimeras for Lower-Toxicity Antiviral Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing consensus interferon therapeutics suffer from severe side effects and low patient compliance due to their pharmacokinetic properties, leading to inadequate viral suppression and high dropout rates.
Innovation Solution
Development of chimeric proteins comprising modified consensus interferon with reduced affinity for the IFNAR receptor, combined with targeting moieties that specifically bind to immune cells or non-cellular structures, allowing for localized therapeutic action and reduced off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If consensus interferon is administered at high concentrations to achieve adequate antiviral activity, then viral suppression is improved, but severe side effects occur including influenza-like symptoms, myalgia, leucopenia, thrombocytopenia, neutropenia, depression, and weight loss
Solution Approach 1:
The patent modifies the consensus interferon molecule by introducing specific amino acid substitutions (e.g., at positions 23, 26, 53, 54, 56, 86, 104, 106, 110, 117, 125, 136) to create variants with altered receptor binding properties. This local modification approach allows the interferon to maintain antiviral activity while reducing binding to certain IFNAR subunits, thereby decreasing systemic side effects while preserving therapeutic efficacy at the target site
Solution Approach 2:
The patent systematically changes the biochemical parameters of consensus interferon by substituting specific amino acids to alter its pharmacokinetic and pharmacodynamic properties. These parameter changes include modifying receptor affinity, serum half-life, and biological activity profile, enabling the development of interferon variants with improved therapeutic windows that maintain efficacy while reducing toxicity
2Reliability
If consensus interferon is administered frequently or at higher doses to maintain serum concentration, then antiviral activity is maintained, but patient compliance decreases due to severe side effects and high dropout rates
Solution Approach 1:
The patent creates interferon variants with dynamically optimized pharmacokinetic properties, particularly extended serum half-life through modified receptor interaction characteristics. This allows the drug to maintain therapeutic serum concentrations for longer periods between doses, enabling less frequent administration schedules that improve patient compliance while maintaining consistent antiviral pressure to prevent viral rebound
3Power
If consensus interferon binds strongly to IFNAR receptor to maximize biological activity, then antiviral effect is enhanced, but serum half-life decreases leading to rapid concentration drop below detection limit by next dose
Solution Approach 1:
The patent introduces specific amino acid substitutions at key positions (e.g., 23, 26, 53, 54, 56, 86, 104, 106, 110, 117, 125, 136) to differentially modify binding affinity for IFNAR1 versus IFNAR2 subunits. This local structural modification creates interferon variants that maintain sufficient receptor binding for biological activity while altering the kinetic profile to extend serum half-life, allowing the drug to remain therapeutic longer without requiring excessive dosing
Data Source
AI summary
The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.